Cargando…

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of developing a skin cancer. Therefore, new therapeutic options such as inhibitors of the mammalian target of rapamycin (mTORi) have been studied to find treatment regimens decreasing the rate of skin cancers....

Descripción completa

Detalles Bibliográficos
Autores principales:	Olszewska, Berenika, Imko-Walczuk, Beata, Dębska-Ślizień, Alicja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258712/ https://www.ncbi.nlm.nih.gov/pubmed/37312910 http://dx.doi.org/10.5114/ada.2023.127637

Ejemplares similares

Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors
por: Cegielska, Agnieszka, et al.
Publicado: (2018)

Demodicosis as a Skin Complication in Organ Transplant Recipients: A Case Series
por: Marquardt-Feszler, Adriana, et al.
Publicado: (2022)

Squamous cell carcinomas in organ transplant recipients. Comparison of histopathological and clinical features of squamous cell carcinoma in patients after organ transplantation to immunocompetent patients
por: Renczyñska-Matysko, Joanna, et al.
Publicado: (2022)

Skin cancer in children after organ transplantation
por: Imko-Walczuk, Beata, et al.
Publicado: (2019)

Demodicosis among immunocompromised patients: a review
por: Marquardt-Feszler, Adriana, et al.
Publicado: (2022)

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
por: Xie, Xishao, et al.
Publicado: (2015)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
por: Llinàs-Mallol, Laura, et al.
Publicado: (2020)

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
por: Geissler, Edward K
Publicado: (2015)

Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
por: Gottlieb, Jens, et al.
Publicado: (2023)

Asymptomatic Bacteriuria in Kidney Transplant Recipients—A Narrative Review
por: Gołębiewska, Justyna E., et al.
Publicado: (2023)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

Calcineurin inhibitor toxicity in a renal transplant recipient
por: Charney, Douglas A., et al.
Publicado: (2009)

Parasitic Infections Associated with Unfavourable Outcomes in Transplant Recipients
por: Wołyniec, Wojciech, et al.
Publicado: (2018)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
por: Campos-Salazar, Antony Brayan, et al.
Publicado: (2018)

The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients
por: Sayilar, Emel Isiktas, et al.
Publicado: (2022)

Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients
por: Ślizień, Zuzanna, et al.
Publicado: (2022)

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients
por: Murray, Susan L., et al.
Publicado: (2020)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

mTOR inhibitor everolimus reduces invasiveness of melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
por: Tylicki, Leszek, et al.
Publicado: (2022)

Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients
por: Tylicki, Leszek, et al.
Publicado: (2021)

Comprehensive Assessment of Eyes in Kidney Transplant Recipients after Recovering from COVID-19
por: Ślizień, Mateusz, et al.
Publicado: (2023)

Gallbladder Pathologies in Kidney Transplant Recipients: Single-Center Experience and a Review of the Literature
por: Dobosz, Łukasz, et al.
Publicado: (2018)

The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK
por: Casabonne, Delphine, et al.
Publicado: (2009)

Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients
por: Ashavaid, T., et al.
Publicado: (2010)

Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients
por: Leyking, Sarah, et al.
Publicado: (2015)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

The Pre-Transplant Drop in Panel-Reactive Antibodies Titer Evaluated Using Complement-Dependent Cytotoxicity (PRA-CDC) and the Risk of Early Acute Rejection in Sensitized Kidney Transplant Recipients
por: Kolonko, Aureliusz, et al.
Publicado: (2018)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

A 10-year monitoring of the eyesight in patients after kidney transplantation
por: Raczyńska, Dorota, et al.
Publicado: (2018)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients
por: Heleniak, Zbigniew T., et al.
Publicado: (2022)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tjk5e1kp3j3b8g0ohqm5qt6ljm